VFA
PRTK

Virtus Fund Advisers’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Virtus Fund Advisers’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$350K Buy
+19,580
New +$409K ﹤0.01% 402

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Virtus Fund Advisers's PRTK Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Paratek Pharmaceuticals, Inc. (PRTK) in Q4 2017: 19,580 shares worth $350K. The stake represents ﹤0.01% of the portfolio and ranks #402 among its holdings.

116 funds tracked by Wall St. Rank hold PRTK as of Q4 2017.

  • Virtus Fund Advisers held 19,580 shares of Paratek Pharmaceuticals, Inc. worth $350K as of Q4 2017.
  • Paratek Pharmaceuticals, Inc. was a new Virtus Fund Advisers position in Q4 2017.
  • Paratek Pharmaceuticals, Inc. made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #402 holding.
  • 116 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.